Ropes & Gray Advises SK Biopharmaceuticals in Worldwide License Agreement With Full-Life Technologies for Radiotherapy Targeting Cancer Cells
September 17, 2024
September 17, 2024
BOSTON, Massachusetts, Sept. 17 -- Ropes and Gray, a law firm, issued the following news:
Ropes & Gray advised South Korean biotechnology company SK Biopharmaceuticals in a in a global licensing agreement with radiotherapy company Full-Life Technologies for exclusive worldwide clinical research, development, manufacturing and commercialization rights to Full-Life's FL-091 radiopharmaceutical compound designed to deliver targeted radiation therapy to a certain receptor protein wh . . .
Ropes & Gray advised South Korean biotechnology company SK Biopharmaceuticals in a in a global licensing agreement with radiotherapy company Full-Life Technologies for exclusive worldwide clinical research, development, manufacturing and commercialization rights to Full-Life's FL-091 radiopharmaceutical compound designed to deliver targeted radiation therapy to a certain receptor protein wh . . .